Drugmaker Akorn Becoming Mighty Oak In Hi-Tech Merger
Mergers are usually more popular with investors in the company being acquired than in the acquirer. Since specialty drugmaker Akorn agreed to buy Hi-Tech Pharmacal, however, its stock has gone up. Akorn's (AKRX) $640 million payout isn't huge by drug-industry standards, but for that price it will nearly double in size, as both companies' annual revenue is running between $200 million and $300 million. The buyout will also address a need raised by
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here